Skip to main content
NewslettersWatchlist

Medicus Pharma Ltd(MDCX-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low2.200
Day High2.200
Open:2.200
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Medicus Pharma Ltd. Announces Closing of Private Placement of Convertible Notes
Newsfile
Medicus Pharma Ltd. Announces Proposed Private Placement of Convertible Notes
AI-generated - The Globe and Mail
Medicus Pharma: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (MDCX)
Newsfile
Medicus Pharma Ltd. Receives FDA Comments on Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Newsfile
Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer
Newsfile
Medicus Pharma Ltd. Publishes Phase 1 Clinical Study Report Demonstrating Safety & Tolerability in All Participants with Basal Cell Carcinoma
Newsfile
Medicus Pharma Ltd. Announces the Filing of a Final Base Shelf Prospectus
Newsfile
Medicus Pharma Ltd. Announces Listing on Frankfurt Stock Exchange
Newsfile
Medicus Pharma Ltd. Submits to the FDA Phase 2 IND Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Newswire.ca
Medicus Pharma Opens the Market
Newsfile
Medicus Pharma Ltd. to Ring the Toronto Stock Exchange Opening Bell on Thursday October 26th 2023; Appoints Paul A. Marchetto, MD, FACS as Chairman of the Scientific Advisory Board
Newsfile
Medicus Pharma Ltd. Announces Appointment of Huma Qamar, MD as Chief Scientific Officer & Head of R&D Program
ACCESSWIRE
The Watchlist by The Market Herald Releases New Interviews with Nextech3D.ai and Medicus Pharma Discussing their Latest News
Newsfile
Medicus Pharma Ltd. Announces Commencement of Trading on TSX Venture Exchange and Appointment of Seasoned Pharma Executive Barry Fishman to the Board of Directors
Newsfile
Medicus Pharma Ltd. Announces Closing of Business Combination

Profile

Medicus Pharma Ltd will carry on the business of pharmaceutical drug development focused initially on SkinJect. The objective of SkinJect is developing and commercializing novel microneedle arrays for the purpose of treating certain skin cancers, initially basal cell carcinoma.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.